SPONSOR
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Total Trials
10
Recruiting
10
Phases
Phase 2, EARLY_Phase 1, Phase 1, Phase 1, Phase 2
Conditions studied: Ovary CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerBreast CancerEarly-stage Breast CancerChronic Myelomonocytic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap NeoplasmsChronic Neutrophilic LeukemiaBRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Breast Cancer.
The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
How many clinical trials has Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, of which 10 are actively recruiting participants. These trials cover conditions including Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins research focus on?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trials span Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Breast Cancer, Early-stage Breast Cancer, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trial?
To participate in a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials with current recruitment status updated daily.
Clinical Trials by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06617923 Phase 2
Recruiting
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Ovary Cancer
NCT05386719
Recruiting
Cardiometabolic Screening Program
Breast Cancer
NCT07071155 EARLY_Phase 1
Recruiting
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Chronic Myelomonocytic Leukemia
NCT06610682 EARLY_Phase 1
Recruiting
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
BRAF V600E Mutation
NCT07424222 Phase 1
Recruiting
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
NCT06796543
Recruiting
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Metastatic Sarcoma
NCT06895564
Recruiting
Proton SBRT for Spinal Metastasis
Spinal Metastasis
NCT06463262
Recruiting
Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma
Chordoma of Spine
NCT06941857 Phase 2
Recruiting
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Pancreatic Cancer
NCT05950139 Phase 1, Phase 2
Recruiting
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
NSCLC Stage IV
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology